{
  "source": "PA-Notification-Rukobia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1323-6\nProgram Prior Authorization/Notification\nMedication Rukobia (fostemsavir)\nP&T Approval Date 8/2020, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nRukobia (fostemsavir), a human immunodeficiency virus type 1 (HIV-1) gp120-directed\nattachment inhibitor, in combination with other antiretroviral(s), is indicated for the treatment\nof HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1\ninfection failing their current antiretroviral regimen due to resistance, intolerance, or safety\nconsiderations.1\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Rukobia\n1. Rukobia will be approved based on both of the following criteria:\na. Patient has been diagnosed with multidrug-resistant HIV-1 infection\n-AND-\nb. Patient is currently taking or will be prescribed an optimized background\nantiretroviral regimen\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Rukobia [Package Insert]. Durham, NC: ViiV Healthcare; February 2024.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Rukobia (fostemsavir)\nChange Control\n8/2020 New program.\n12/2020 Revised criteria language related to optimized background regimen.\n12/2021 Annual review with no change to clinical criteria.\n12/2022 Annual review with no change to cl",
    "rol\n8/2020 New program.\n12/2020 Revised criteria language related to optimized background regimen.\n12/2021 Annual review with no change to clinical criteria.\n12/2022 Annual review with no change to clinical criteria. Added state mandate\nfootnote and updated reference.\n12/2023 Annual review with no changes to coverage criteria.\n12/2024 Annual review with no changes to coverage criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}